Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301762 | 0.94 | PDE4A (0.58) | PDE4APDE4DPDE4B | |
| SCHEMBL19017997 | 0.91 | PDE4A (0.61) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL434451 | 0.91 | PDE4A (0.66) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL3305354 | 0.90 | PDE4A (0.49) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL5751710 | 0.90 | PDE4A (0.65) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL6836821 | 0.90 | PDE4A (0.65) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL3304195 | 0.89 | PDE4A (0.77) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL18857435 | 0.89 | PDE4A (0.48) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL3304549 | 0.88 | PDE4A (0.62) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL7702419 | 0.87 | PDE4A (0.81) | PDE4APDE4DPDE4BPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114951-B9 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2015-09-02 | — | — | EP | claimed |
| US-8338431-B2 | Phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2012-12-25 | — | — | US | claimed |
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2010-04-22 | — | — | US | claimed |
| EP-3070091-B1 | BENZODIOXOLE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2019-04-17 | — | — | EP | disclosed |
| EP-3070091-B1 | BENZODIOXOLE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2019-04-17 | — | — | EP | disclosed |
| EP-3157930-B1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | LEO PHARMA AS (DK) | 2018-10-17 | — | — | EP | disclosed |
| US-9908894-B2 | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | LEO PHARMA A/S (DK) | 2018-03-06 | — | — | US | disclosed |
| US-20170137438-A1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | UNION therapeutics A/S (DK) | 2017-05-18 | — | — | US | disclosed |
| US-9637499-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2017-05-02 | — | — | US | disclosed |
| US-9637499-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2017-05-02 | — | — | US | disclosed |
| US-9637499-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2017-05-02 | — | — | US | disclosed |
| US-8338431-B2 | Phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2012-12-25 | — | — | US | disclosed |
| US-8338431-B2 | Phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2012-12-25 | — | — | US | disclosed |
| WO-2011160632-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-12-29 | — | — | WO | disclosed |
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2010-04-22 | — | — | US | disclosed |
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2010-04-22 | — | — | US | disclosed |
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2010-04-22 | — | — | US | disclosed |
| EP-2114951-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008104175-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104175-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE5A, PDE3B | PDE4A 6/4885PDE4D 9/4885PDE4B 10/4885 |
| US-20170137438-A1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | PDE4B, PDE4A, PDE3B | PDE4A 2/4885PDE4D 8/4885PDE4B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.